---
id: "70a725ab-88fb-463f-8b12-faaba421e4ed"
type: "Organization"
name: "Calico"
slug: "calico"
canonical: "https://groundingwiki.com/en/organizations/calico/"
markdown: "https://groundingwiki.com/en/organizations/calico/index.md"
language: en
last_reviewed: 2026-09-29
same_as:
  - "https://www.calicolabs.com/"
  - "https://wikidata.org/wiki/Q14932155"
  - "https://wikidata.org/wiki/Q20800404"
---

# Calico

Calico is a research company that studies the biology of aging and develops potential treatments. [1]

## Core facts

- **Entity type:** Organization

- **Legal name:** Calico Life Sciences LLC — [2] first-party, checked 29 Sept 2026

- **Headquarters:** South San Francisco, California, United States — [3] first-party, checked 29 Sept 2026

- **Country:** United States — [3] first-party, checked 29 Sept 2026

- **Headquarters address:** 1170 Veterans Blvd, South San Francisco, CA 94080, United States — [3] first-party, checked 29 Sept 2026

- **Official website:** [calicolabs.com](https://www.calicolabs.com/) — [1] first-party, checked 29 Sept 2026

## What is Calico?

Calico combines basic research into aging biology with computational methods and drug development. Its published approach studies model systems and human data, while its clinical-stage programmes investigate potential therapies for age-related and other serious diseases. These programmes remain investigational unless separately approved. — [5] first-party, checked 29 Sept 2026; [1] first-party, checked 29 Sept 2026; [6] first-party, checked 29 Sept 2026

## History

- **2013:** Calico launched in 2013 with support from Google to study the biology of aging and translate research into potential medicines. — [7] first-party, checked 29 Sept 2026

- **2015:** Calico says its own laboratories became operational in 2015. — [7] first-party, checked 29 Sept 2026

- **2024:** In May 2024, Calico and the Broad Institute extended their collaboration through September 2029, adding a focus on age-related neurodegeneration. — [8] first-party, checked 29 Sept 2026

- **2026:** In May 2026, Calico and Nexo announced a multi-target collaboration to discover and develop small-molecule therapies for challenging disease targets. — [9] first-party, checked 29 Sept 2026

## Contributions and work

- **Collaboration Model:** Calico works with external biopharmaceutical and academic organizations on research and drug discovery. — [6] first-party, checked 29 Sept 2026

- **Computational Biology:** Calico combines biology research with advanced computing, machine learning, computer vision, and analysis of genotypic and phenotypic data. — [6] first-party, checked 29 Sept 2026

- **Focus:** Calico studies the biology of aging and age-related diseases, with work spanning basic research and translation toward potential interventions. — [6] first-party, checked 29 Sept 2026

- **Model Systems:** Calico’s basic-research programme studies aging in yeast, C. elegans, mice, and human cells and tissues, alongside human genetic datasets. — [6] first-party, checked 29 Sept 2026

- **Translation:** Calico links basic research with therapeutic discovery and clinical development for diseases associated with aging. — [1] first-party, checked 29 Sept 2026

## Products

- **Drug Development:** Drug development aimed at translating biological findings into potential treatments. — [1] first-party, checked 29 Sept 2026

- **Fosigotifator:** Fosigotifator \(ABBV-CLS-7262\) is an investigational eIF2B activator developed by Calico for vanishing white matter disease; it is not an approved medicine. — [5] first-party, checked 29 Sept 2026

- **Fosigotifator Clinical Stage:** Calico reported fosigotifator in a Phase 1b/2 clinical trial for vanishing white matter disease as of June 23, 2026. — [5] first-party, checked 29 Sept 2026

- **Fosigotifator Regulatory Status:** The U.S. FDA granted fosigotifator Breakthrough Therapy Designation for vanishing white matter disease on June 23, 2026; the designation is not marketing approval. — [5] first-party, checked 29 Sept 2026

## Leadership

- **Chief Business Officer:** Jonathan W. Lewis is Calico’s Chief Business Officer. — [10] first-party, checked 29 Sept 2026

- **Chief Financial Officer:** John Whiting is Calico’s Chief Financial Officer. — [10] first-party, checked 29 Sept 2026

- **Founder Ceo:** Arthur D. Levinson is Calico’s Founder and Chief Executive Officer. — [10] first-party, checked 29 Sept 2026

- **Head Discovery Technologies:** Dan Eaton is Calico’s Head of Discovery Technologies. — [10] first-party, checked 29 Sept 2026

- **Head Drug Discovery Development Sciences:** Philip Kym leads Drug Discovery and Development Sciences at Calico. — [10] first-party, checked 29 Sept 2026

- **Head Human Biology Genetics:** Calico announced Joe Arron as Head of Human Biology and Genetics in February 2026. — [11] first-party, checked 29 Sept 2026

- **Head Research Development:** Joe Arron is Calico’s Head of Research & Development. — [10] first-party, checked 29 Sept 2026

- **Vice President Aging Research:** Cynthia Kenyon is Calico’s Vice President of Aging Research. — [10] first-party, checked 29 Sept 2026

## Relationships

- **founded by:** [Arthur D. Levinson](https://groundingwiki.com/en/people/arthur-d-levinson/index.md) — [5] first-party, checked 29 Sept 2026

- **founded by:** [Alphabet Inc.](https://groundingwiki.com/en/organizations/alphabet-inc/index.md) — [5] first-party, checked 29 Sept 2026

- **subsidiary of:** [Alphabet Inc.](https://groundingwiki.com/en/organizations/alphabet-inc/index.md) — [12] structured public data, checked 22 Sept 2026

- **owned by:** XXVI Holdings — [4] structured public data, checked 29 Sept 2026

- **created by:** [Google](https://groundingwiki.com/en/companies/google/index.md) — [4] structured public data, checked 29 Sept 2026

- **created by:** [Arthur D. Levinson](https://groundingwiki.com/en/people/arthur-d-levinson/index.md) — [4] structured public data, checked 29 Sept 2026

- **subsidiary of:** [Alphabet Inc.](https://groundingwiki.com/en/organizations/alphabet-inc/index.md) — [4] structured public data, checked 29 Sept 2026

## Sources
1. [Calico — Home](https://calicolabs.com/)
   - Publisher: Calico
   - Type: first-party
   - Checked: 29 Sept 2026
   - Evidence:
     - Definition: "The official Calico site says Calico studies the biology of aging and healthspan."
     - Official website: "Calico’s official homepage presents its research, clinical programmes, company information and navigation on the calicolabs.com domain."
     - What is Calico?: "Calico’s homepage describes basic research, advanced computational biology, machine learning, drug development and clinical programmes, and distinguishes potential medicines from approved treatments."
     - Translation: "Calico describes moving from basic research and computational biology through drug development toward potential clinical impact; it also lists clinical research and ongoing therapy programmes."
     - Drug Development: "The official Calico site describes drug development and translating biological insights into potential treatments."
2. [Global Privacy Policy](https://calicolabs.com/privacy-policy)
   - Publisher: Calico
   - Type: first-party
   - Checked: 29 Sept 2026
   - Evidence:
     - Legal name: "Calico’s current privacy policy identifies the responsible organization as Calico Life Sciences LLC."
3. [Contact Us](https://calicolabs.com/contact-us)
   - Publisher: Calico
   - Type: first-party
   - Checked: 29 Sept 2026
   - Evidence:
     - Headquarters: "Calico’s current contact page lists its office in South San Francisco, California."
     - Country: "Calico’s official contact page gives its office in South San Francisco, California, United States."
     - Headquarters address: "Calico’s current contact page lists 1170 Veterans Boulevard, South San Francisco, California 94080 as its office address."
4. [Calico \(Q14932155\)](https://wikidata.org/wiki/Q14932155)
   - Publisher: Wikidata
   - Type: structured public data
   - Checked: 29 Sept 2026
   - Evidence:
     - owned by: "Wikidata P127 links Calico to XXVI Holdings."
     - created by: "Wikidata P112 links Calico to Google."
     - created by: "Wikidata P112 links Calico to Arthur D. Levinson."
     - subsidiary of: "Wikidata P749 links Calico to Alphabet Inc.."
5. [Fosigotifator Granted FDA Breakthrough Therapy Designation](https://calicolabs.com/press/calico-life-sciences-announces-fosigotifator-granted-breakthrough-therapy-designation-by-the-u-s-fda-for-the-treatment-of-vanishing-white-matter-disease)
   - Publisher: Calico
   - Type: first-party
   - Checked: 29 Sept 2026
   - Evidence:
     - What is Calico?: "Calico’s June 2026 release documents one investigational therapy program and explicitly states fosigotifator is not approved by any regulatory authority."
     - Fosigotifator: "Calico’s June 23, 2026 release identifies fosigotifator as an investigational eIF2B activator it developed for vanishing white matter disease and explicitly states it has not been approved by a regulatory authority."
     - Fosigotifator Clinical Stage: "The company’s dated June 23, 2026 release says the investigational drug was in a Phase 1b/2 trial evaluating safety, tolerability, pharmacokinetics and exploratory efficacy."
     - Fosigotifator Regulatory Status: "Calico announced the FDA designation on June 23, 2026 and separately states fosigotifator remains investigational and unapproved by any regulatory authority."
     - founded by: "Calico’s June 2026 press release identifies Arthur D. Levinson as a founder; Calico’s current people page lists him as Founder & CEO."
     - founded by: "Calico’s June 2026 official press release describes Calico as founded by Alphabet Inc. and Arthur D. Levinson."
6. [Research & Technology](https://calicolabs.com/research-technology)
   - Publisher: Calico
   - Type: first-party
   - Checked: 29 Sept 2026
   - Evidence:
     - What is Calico?: "Calico’s Research & Technology page describes basic research in model organisms and human genetic data, computational methods, and translation toward interventions."
     - Collaboration Model: "Calico’s research page describes collaboration with external biopharmaceutical companies and academic institutions as part of its research approach."
     - Computational Biology: "Calico’s technology section describes machine learning, software engineering, data science, advanced computer vision and analysis of genotypic and phenotypic data in its research."
     - Focus: "Calico describes studying aging biology and age-related disease and translating discoveries into potential interventions."
     - Model Systems: "Calico lists yeast, C. elegans, mice, human cells and tissues as model systems and says computational researchers also use available human genetic datasets."
7. [Our Story: Taking a long-term view on tackling aging and increasing healthspan](https://calicolabs.com/story/our-story-taking-a-long-term-view-on-tackling-aging-and-increasing-healthspan)
   - Publisher: Calico
   - Type: first-party
   - Checked: 29 Sept 2026
   - Evidence:
     - 2013: "Calico’s official company history says it launched in 2013 with support from Google and describes the initial dual mission of aging-biology research and translation into medicines."
     - 2015: "Calico’s company history states that its own labs became operational in 2015 after establishing research-partner collaborations."
8. [Calico and Broad Institute Extend Collaboration](https://calicolabs.com/press/calico-and-broad-institute-extend-collaboration-adding-focus-on-age-related-neurodegeneration)
   - Publisher: Calico
   - Type: first-party
   - Checked: 29 Sept 2026
   - Evidence:
     - 2024: "The joint announcement states that the renewed agreement runs through September 2029 and adds age-related neurodegeneration to ongoing aging-biology and early-stage drug-discovery work."
9. [Calico and Nexo Collaboration](https://calicolabs.com/press/calico-and-nexo-enter-into-collaboration-to-discover-and-develop-small-molecule-therapies-for-age-related-diseases)
   - Publisher: Calico
   - Type: first-party
   - Checked: 29 Sept 2026
   - Evidence:
     - 2026: "The companies’ May 21, 2026 announcement says they will jointly pursue targets nominated by Calico, using Nexo’s chemistry platform; Calico will lead further development and commercialization of resulting programmes."
10. [People and Leadership](https://calicolabs.com/people)
   - Publisher: Calico
   - Type: first-party
   - Checked: 29 Sept 2026
   - Evidence:
     - Chief Business Officer: "Calico’s current leadership roster lists Jonathan W. Lewis as Chief Business Officer."
     - Chief Financial Officer: "Calico’s current leadership roster lists John Whiting as Chief Financial Officer."
     - Founder Ceo: "Calico’s current leadership roster identifies Arthur D. Levinson as Founder & CEO; his profile says he co-founded Calico and was named CEO in September 2013."
     - Head Discovery Technologies: "Calico’s current leadership roster lists Dan Eaton as Head of Discovery Technologies."
     - Head Drug Discovery Development Sciences: "Calico’s current leadership roster lists Philip Kym as Head of Drug Discovery and Development Sciences."
     - Head Research Development: "Calico’s current leadership roster lists Joe Arron as Head of Research & Development."
     - Vice President Aging Research: "Calico’s current leadership roster lists Cynthia Kenyon as Vice President, Aging Research."
11. [Calico Appoints Joseph R. Arron as Head of Human Biology and Genetics](https://calicolabs.com/press/calico-appoints-joseph-r-arron-m-d-ph-d-as-head-of-human-biology-and-genetics)
   - Publisher: Calico
   - Type: first-party
   - Checked: 29 Sept 2026
   - Evidence:
     - Head Human Biology Genetics: "Calico’s February 5, 2026 appointment announcement identifies Joseph R. Arron as Head of Human Biology and Genetics."
12. [Alphabet Inc. — Wikidata](https://wikidata.org/wiki/Q20800404)
   - Publisher: Wikidata
   - Type: structured public data
   - Checked: 22 Sept 2026
   - Evidence:
     - subsidiary of: "Wikidata P355 links Alphabet Inc. to Calico."

HTML version: https://groundingwiki.com/en/organizations/calico/
Methodology: https://groundingwiki.com/methodology/
Source policy: https://groundingwiki.com/source-policy/
Corrections: https://groundingwiki.com/corrections/?entity=Calico
